Get the latest news, insights, and market updates on DCTH (Delcath Systems, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT
Delcath Systems, Inc. (NASDAQ:DCTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 5, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, Inc. (NASDAQ:DCTH), but lowered the price target from $31 to $30. Earlier on November 4, Delcath Systems, Inc. (NASDAQ:DCTH) released results for its […] Nov 18, 2025 - $DCTH
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
QUEENSBURY, N.Y., November 18, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled "Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion," was published in the Journal of Vascular and Inter Nov 18, 2025 - $DCTH
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y., November 14, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to six individuals whose employment commenced in either September 2025 or October 2025. Nov 14, 2025 - $DCTH
Delcath Systems (DCTH): Evaluating Valuation After Third Quarter Profitability Turnaround
Delcath Systems (DCTH) just posted its third quarter earnings, showing a shift to profitability compared to last year’s loss. For investors, this marks a pivotal change in the company’s financial outlook. See our latest analysis for Delcath Systems. After swinging to profitability, Delcath Systems’ share price has seen renewed attention. However, near-term momentum has cooled with a 30-day share price return of -17.6%. Still, its three-year total shareholder return of 207.9% underscores just... Nov 12, 2025 - $DCTH
Delcath Systems (DCTH) Profitability and Margin Gains Reinforce Value Bull Case, Despite Dilution Concerns
Delcath Systems (DCTH) has achieved profitability with a notable improvement in net profit margins, joining the ranks of medical technology firms posting high-quality earnings. Analysts now forecast earnings growth of 48.78% per year, while revenue is set to expand at 23.5% per year. Both figures are well above US market averages. Following this strong performance, the company’s price-to-sales ratio of 3.9x comes in well below the peer average of 13x, and the current trading price of $8.68... Nov 6, 2025 - $DCTH
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y., November 06, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Nov 6, 2025 - $DCTH
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of 0.00% and +0.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $DCTH
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y., November 04, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Nov 4, 2025 - $DCTH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple